Drug intelligence / Profile preview

IGT-512

Development stage: Preclinical
Lead developer: Ingenia Therapeutics
Modality: Antibody-Based Therapeutics, Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
Administration: Parenteral

Overview

IGT-512 is an investigational antibody drug developed by Ingenia Therapeutics for the treatment of cancer. It utilizes Ingenia's proprietary technology to modify endothelial cell signaling, specifically acting as a TIE-2 receptor agonist. The TIE-2 receptor is involved in angiogenesis and vascular stability, making it a target of interest in oncology for modulating tumor vasculature. As of the latest updates, IGT-512 remains in early research and discovery phases with no orphan drug designation or regulatory approvals[1][2].

Other names: IGT 512IGT512IGT-512

Targets

TEK (Tie2)

Beyond the preview

Go deeper on IGT-512.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on IGT-512.

Explore the full profile